Cargando…

The quality of antiretroviral medicines: an uncertain problem

OBJECTIVES: Substandard and falsified (SF) antiretrovirals (ARVs) risk poor outcomes and drug resistance, potentially affecting millions of people in need of treatment and prevention. We assessed the available evidence on SF ARV and related medical devices to discuss their potential public health im...

Descripción completa

Detalles Bibliográficos
Autores principales: Do, Ngan Thi, Boupha, Phonepasith, Newton, Paul N, Caillet, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030546/
https://www.ncbi.nlm.nih.gov/pubmed/36921990
http://dx.doi.org/10.1136/bmjgh-2022-011423
_version_ 1784910400135888896
author Do, Ngan Thi
Boupha, Phonepasith
Newton, Paul N
Caillet, Céline
author_facet Do, Ngan Thi
Boupha, Phonepasith
Newton, Paul N
Caillet, Céline
author_sort Do, Ngan Thi
collection PubMed
description OBJECTIVES: Substandard and falsified (SF) antiretrovirals (ARVs) risk poor outcomes and drug resistance, potentially affecting millions of people in need of treatment and prevention. We assessed the available evidence on SF ARV and related medical devices to discuss their potential public health impact. METHODS: Searches were conducted in Embase, PubMed, Google, Google Scholar, Web of Science and websites with interest in ARV quality in English and French up to 30 November 2021. Publications reporting on the prevalence of SF ARV were assessed in a quantitative analysis using the Medicine Quality Assessment Reporting Guidelines (MEDQUARG). RESULTS: We included 205 publications on SF ARV and 11 on SF medical devices. Nineteen prevalence surveys of SF ARV, published between 2003 and 2021, were included, with no surveys relevant to SF medical devices. The prevalence survey sample size ranged from 3 to 2630 samples (median (Q1–Q3): 16.0 (10.5–44.5); 3 (15.8%) used random outlet sampling methods. Of the 3713 samples included in the prevalence surveys, 1.4% (n=51) failed at least one test. Efavirenz, nevirapine and lamivudine-nevirapine-stavudine combination were the most surveyed ARV with failure frequencies of 3.6% (7/193), 2.6% (5/192) and 2.8% (5/177), respectively. The median (Q1%–Q3%) concordance with the MEDQUARG criteria was 42.3% (34.6%–55.8%). CONCLUSION: These results suggest that there are few data in the public domain of the quality of ARV in supply chains; the proportion of SF ARV is relatively low in comparison to other classes of essential medicines. Even a low proportion of the ARV supply chain being poor quality could make a large difference in the HIV/AIDS international landscape. The 95-95-95 target for 2026 and other international targets could be greatly hampered if even 1% of the millions of people taking ARV (for both prevention and prophylaxis) receive medicines that do not meet quality standards. More surveillance of SF ARV is needed to ensure issues are detected.
format Online
Article
Text
id pubmed-10030546
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-100305462023-03-23 The quality of antiretroviral medicines: an uncertain problem Do, Ngan Thi Boupha, Phonepasith Newton, Paul N Caillet, Céline BMJ Glob Health Original Research OBJECTIVES: Substandard and falsified (SF) antiretrovirals (ARVs) risk poor outcomes and drug resistance, potentially affecting millions of people in need of treatment and prevention. We assessed the available evidence on SF ARV and related medical devices to discuss their potential public health impact. METHODS: Searches were conducted in Embase, PubMed, Google, Google Scholar, Web of Science and websites with interest in ARV quality in English and French up to 30 November 2021. Publications reporting on the prevalence of SF ARV were assessed in a quantitative analysis using the Medicine Quality Assessment Reporting Guidelines (MEDQUARG). RESULTS: We included 205 publications on SF ARV and 11 on SF medical devices. Nineteen prevalence surveys of SF ARV, published between 2003 and 2021, were included, with no surveys relevant to SF medical devices. The prevalence survey sample size ranged from 3 to 2630 samples (median (Q1–Q3): 16.0 (10.5–44.5); 3 (15.8%) used random outlet sampling methods. Of the 3713 samples included in the prevalence surveys, 1.4% (n=51) failed at least one test. Efavirenz, nevirapine and lamivudine-nevirapine-stavudine combination were the most surveyed ARV with failure frequencies of 3.6% (7/193), 2.6% (5/192) and 2.8% (5/177), respectively. The median (Q1%–Q3%) concordance with the MEDQUARG criteria was 42.3% (34.6%–55.8%). CONCLUSION: These results suggest that there are few data in the public domain of the quality of ARV in supply chains; the proportion of SF ARV is relatively low in comparison to other classes of essential medicines. Even a low proportion of the ARV supply chain being poor quality could make a large difference in the HIV/AIDS international landscape. The 95-95-95 target for 2026 and other international targets could be greatly hampered if even 1% of the millions of people taking ARV (for both prevention and prophylaxis) receive medicines that do not meet quality standards. More surveillance of SF ARV is needed to ensure issues are detected. BMJ Publishing Group 2023-03-15 /pmc/articles/PMC10030546/ /pubmed/36921990 http://dx.doi.org/10.1136/bmjgh-2022-011423 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Research
Do, Ngan Thi
Boupha, Phonepasith
Newton, Paul N
Caillet, Céline
The quality of antiretroviral medicines: an uncertain problem
title The quality of antiretroviral medicines: an uncertain problem
title_full The quality of antiretroviral medicines: an uncertain problem
title_fullStr The quality of antiretroviral medicines: an uncertain problem
title_full_unstemmed The quality of antiretroviral medicines: an uncertain problem
title_short The quality of antiretroviral medicines: an uncertain problem
title_sort quality of antiretroviral medicines: an uncertain problem
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030546/
https://www.ncbi.nlm.nih.gov/pubmed/36921990
http://dx.doi.org/10.1136/bmjgh-2022-011423
work_keys_str_mv AT donganthi thequalityofantiretroviralmedicinesanuncertainproblem
AT bouphaphonepasith thequalityofantiretroviralmedicinesanuncertainproblem
AT newtonpauln thequalityofantiretroviralmedicinesanuncertainproblem
AT cailletceline thequalityofantiretroviralmedicinesanuncertainproblem
AT donganthi qualityofantiretroviralmedicinesanuncertainproblem
AT bouphaphonepasith qualityofantiretroviralmedicinesanuncertainproblem
AT newtonpauln qualityofantiretroviralmedicinesanuncertainproblem
AT cailletceline qualityofantiretroviralmedicinesanuncertainproblem